Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial.

Autor: Holmberg-Thydén, Staffan, Dufva, Inge Høgh, Gang, Anne Ortved, Breinholt, Marie Fredslund, Schejbel, Lone, Andersen, Mette Klarskov, Kadivar, Mohammad, Svane, Inge Marie, Grønbæk, Kirsten, Hadrup, Sine Reker, El Fassi, Daniel

Publikováno v: Cancer Immunology, Immunotherapy; Feb2022, Vol. 71 Issue 2, p433-444, 12p

Oral Vitamin C Supplementation to Azacitidine in Patients with Myeloid Cancer: Normalization of Plasma Vitamin C Induces Epigenetic Changes

Autor: Gillberg, Linn ^*, Ørskov, Andreas Due ^*, Nasif, Ammar ^*, Otani, Hitoshi ^*, Madaj, Zachary ^*, Hansen, Jakob Werner ^*, Mogensen, Johanne Bay ^*, Liu, Minmin ^*, Dufva, Inge Høgh ^*, Jens, Lykkesfeldt ^*, Hajkova, Petra ^*, Jones, Peter A. ^*, Grønbæk, Kirsten

Publikováno v: In Blood 29 November 2018 132 Supplement 1:3079-3079

High Early Death Rate With Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia confirmed in unselected patients: Results of a Population-based Registry Study

Autor: Nørgaard, Jan M., Østgård, Lene Sofie Granfeldt, Kjeldsen, Eigil, Holm, Mette S., Andersen, Mette K., Nielsen, Ove J., Kjeldsen, Lars, Kallenbach, Maria, Severinsen, Marianne Tang, Johansen, Preben, Friis, Lone Smidstrup, Weber, Duruta, Kerndrup, Gitte Birk, Preiss, Birgitte Strange, Jensen, Morten K., Dufva, Inge Høgh, Timshel, Susanne, Brown, Peter

Publikováno v: Nørgaard, J M, Østgård, L S G, Kjeldsen, E, Holm, M S, Andersen, M K, Nielsen, O J, Kjeldsen, L, Kallenbach, M, Severinsen, M T, Johansen, P, Friis, L S, Weber, D, Kerndrup, G B, Preiss, B S, Jensen, M K, Dufva, I H, Timshel, S & Brown, P 2012, ' High Early Death Rate With Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia confirmed in unselected patients: Results of a Population-based Registry Study ', European Cancer Rehabilitation & Survivorship Symposium 2012, København, Denmark, 17/09/2012-18/09/2012 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::b4d5103162dac54da463959c4f623382
https://portal.findresearcher.sdu.dk/da/publications/98d520ee-fd95-4a26-9000-f151e4747564

Dasatinib. En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukaemi

Autor: Bjerrum, Ole Weis, Dufva, Inge Høgh, Stentoft, Jesper, Hasselbalch, Hans Carl

Publikováno v: Bjerrum, O W, Dufva, I H, Stentoft, J & Hasselbalch, H C 2008, ' Dasatinib. En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukaemi. ', Ugeskrift for Laeger, bind 170, nr. 5, s. 331-3 .
Bjerrum, O W, Dufva, I H, Stentoft, J & Hasselbalch, H C 2008, ' Dasatinib. En ny tyrosinkinaseinhibitor til behandling af kronisk myeloid leukaemi ', Ugeskrift for læger, bind 170, nr. 5, s. 331-333 .

Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d7c9f9bd8040b487261a5672bc81f36e
https://pure.au.dk/portal/da/publications/dasatinib-en-ny-tyrosinkinaseinhibitor-til-behandling-af-kronisk-myeloid-leukaemi(970d5360-da3f-11dc-bc43-000ea68e967b).html